In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Coherus Oncology Inc (NASDAQ: CHRS) closed at $0.97 in the last session, down -3.96% from day before closing price of $1.01. In other words, the price has decreased by -$3.96 from its previous closing price. On the day, 1.45 million shares were traded. CHRS stock price reached its highest trading level at $1.04 during the session, while it also had its lowest trading level at $0.95.
Ratios:
We take a closer look at CHRS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 224.92. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 112455016 and an Enterprise Value of 329546272. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.57. Its current Enterprise Value per Revenue stands at 1.21 whereas that against EBITDA is -4.236.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.92, which has changed by -0.32167834 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 16.95%, while the 200-Day Moving Average is calculated to be -5.85%.
Shares Statistics:
According to the various share statistics, CHRS traded on average about 1.41M shares per day over the past 3-months and 1413770 shares per day over the past 10 days. A total of 115.91M shares are outstanding, with a floating share count of 105.41M. Insiders hold about 9.07% of the company’s shares, while institutions hold 51.03% stake in the company. Shares short for CHRS as of 1752537600 were 31228059 with a Short Ratio of 22.18, compared to 1749772800 on 31942421. Therefore, it implies a Short% of Shares Outstanding of 31228059 and a Short% of Float of 28.01.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 4.0 analysts. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.17 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$0.81 and -$1.23 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$0.68, with 4.0 analysts recommending between -$0.21 and -$1.15.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $9.38M. It ranges from a high estimate of $11.31M to a low estimate of $5M. As of the current estimate, Coherus Oncology Inc’s year-ago sales were $64.98MFor the next quarter, 7 analysts are estimating revenue of $12.13M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $5M.
A total of 7 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $81.5M, while the lowest revenue estimate was $21.05M, resulting in an average revenue estimate of $48.35M. In the same quarter a year ago, actual revenue was $266.96MBased on 7 analysts’ estimates, the company’s revenue will be $95.17M in the next fiscal year. The high estimate is $186.71M and the low estimate is $27.75M.
